Mission Statement, Vision, & Core Values of HUTCHMED (China) Limited (HCM)

Are you curious about what drives a leading biopharmaceutical company? Delve into the core of HUTCHMED (China) Limited (HCM), a company dedicated to discovering and developing innovative medicines, and explore the mission, vision, and core values that shape its path. How do these guiding principles translate into real-world impact, especially when HUTCHMED reported a $37.7 million net income in 2024 and total oncology products in-market sales soared by 134% to $501.0 million?

Discover how HUTCHMED's commitment to innovation, pragmatism, collaboration, and efficiency fuels its global commercial progress and pipeline advancements. What strategic decisions and values underpin their goal to improve lives globally, and how do they reflect in their financial achievements, such as the $290.6 million in ex-China in-market sales of FRUZAQLA® by Takeda in 2024?

HUTCHMED (China) Limited (HCM) An Overview of

HUTCHMED (China) Limited (HCM) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics, particularly in oncology and immunology. Founded in 2000, HUTCHMED has grown into a globally-recognized firm with a strong presence in China. As of April 2025, the company continues to advance its pipeline of drug candidates and expand its commercial operations.

HUTCHMED's portfolio includes several marketed products and numerous clinical-stage drug candidates. The company's key products include:

• Elunate® (fruquintinib): Approved for the treatment of metastatic colorectal cancer in China.
• Sulanda® (surufatinib): Approved for neuroendocrine tumors in the U.S. and China.
• Orpathys® (savolitinib): Approved for non-small cell lung cancer in China.

These products have driven substantial revenue growth for HUTCHMED. In 2024, Elunate sales reached $147.2 million, representing a 31% increase compared to the previous year. Sulanda generated $73.6 million in sales, and Orpathys contributed $29.1 million. Overall, HUTCHMED reported record-breaking revenue of $826.6 million for the year ended December 31, 2024, marking a 23% increase year-over-year. This growth was primarily fueled by increased sales of its self-marketed oncology drugs and partnered products.

HUTCHMED has also seen significant growth in its international markets. The U.S. Food and Drug Administration (FDA) approved Sulanda for advanced extra-pancreatic neuroendocrine tumors in early 2024, opening new revenue streams for the company. Moreover, the company's R&D investments remain robust, with $338.1 million spent in 2024 to advance its pipeline of novel drug candidates. As of December 31, 2024, HUTCHMED's cash and cash equivalents totaled $673.4 million, providing a solid foundation for future growth and development.

HUTCHMED stands as a leader in the biopharmaceutical industry, particularly in China, due to its strategic focus on oncology and immunology, its innovative drug development capabilities, and its successful commercialization efforts. To delve deeper into HUTCHMED's journey, its mission, and its operational framework, explore: HUTCHMED (China) Limited (HCM): History, Ownership, Mission, How It Works & Makes Money

HUTCHMED (China) Limited (HCM) Mission Statement

The mission statement of HUTCHMED (China) Limited (HCM) reflects its dedication to discovering, developing, and commercializing innovative therapeutics. This commitment addresses unmet medical needs, particularly in oncology and immunology, thereby improving patient health outcomes worldwide. The company's strategic focus involves integrating research and development with commercial capabilities to bring novel medicines to global markets.

HUTCHMED's mission is composed of several core elements:

• Innovation: The company prioritizes the discovery and development of novel therapeutic agents.
• Global Impact: HUTCHMED aims to address medical needs internationally, extending its reach beyond China.
• Integration: By combining R&D with commercial functions, HUTCHMED ensures effective translation of scientific advancements into accessible medicines.

HUTCHMED focuses on creating innovative treatments for cancer and immunological disorders. According to their 2024 report, over 500 scientists and staff are dedicated to R&D, highlighting the company's investment in innovation. This investment aims to develop therapies that offer significant improvements over existing treatments, addressing critical gaps in patient care.

The company's commitment to global impact is evident in its efforts to commercialize products in various markets, including the United States and Europe. As of 2024, HUTCHMED has several ongoing clinical trials globally. These trials are designed to evaluate the safety and efficacy of their drug candidates across diverse patient populations, supporting the mission of improving health outcomes on a broad scale.

Integrating research with commercial capabilities is a key aspect of HUTCHMED's operational strategy. This approach allows for a streamlined process from drug discovery to market availability. In 2024, HUTCHMED reported $870.7 million in total revenue, reflecting the successful commercialization of its innovative products. This integration ensures that scientific advancements are efficiently translated into accessible medicines, reinforcing the mission of delivering high-quality healthcare solutions.

Additional insights about the company and its investors can be found at: Exploring HUTCHMED (China) Limited (HCM) Investor Profile: Who’s Buying and Why?

HUTCHMED (China) Limited (HCM) Vision Statement of

HUTCHMED (China) Limited (HCM) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. Understanding its mission, vision, and core values provides insight into the company's strategic objectives and operational philosophy. You can find more about HUTCHMED's background in this article: HUTCHMED (China) Limited (HCM): History, Ownership, Mission, How It Works & Makes Money.

HUTCHMED’s mission is centered on discovering, developing, and commercializing innovative therapeutics to address unmet medical needs. This mission drives the company’s focus on oncology and immunology, aiming to transform the treatment landscape for patients worldwide. HUTCHMED's commitment is evident in its pipeline of drug candidates and its strategic collaborations.

HUTCHMED envisions becoming a leading global biopharmaceutical company originating from China. This vision encompasses several key aspects:

• Innovation: HUTCHMED aims to be at the forefront of pharmaceutical innovation, continually developing novel therapies.
• Global Reach: The company seeks to expand its presence and impact globally, bringing its innovative medicines to patients around the world.
• Leadership: HUTCHMED aspires to be a leader in the biopharmaceutical industry, setting new standards for drug development and commercialization.

HUTCHMED’s core values underpin its operations and strategic decision-making:

• Integrity: Upholding the highest ethical standards in all its activities.
• Innovation: Fostering a culture of creativity and continuous improvement.
• Collaboration: Working together with partners and stakeholders to achieve common goals.
• Patient-Centricity: Prioritizing the needs of patients in everything the company does.

These core values guide HUTCHMED in its pursuit of scientific excellence and its commitment to making a difference in the lives of patients. For example, in the fiscal year 2024, HUTCHMED invested heavily in R&D, allocating over $300 million to advance its pipeline of drug candidates. This investment reflects the company's dedication to innovation and its long-term vision of bringing transformative medicines to market.

HUTCHMED's strategic goals are reflected in its recent achievements. In 2024, the company reported total revenues of $850 million, driven by the commercial success of its key products and strategic partnerships. This financial performance underscores HUTCHMED's ability to execute its vision and deliver value to its shareholders.

HUTCHMED (China) Limited (HCM) Core Values of

HUTCHMED (China) Limited (HCM) operates with a set of core values that guide its operations and strategic decisions. These values reflect the company's commitment to innovation, integrity, and improving patient outcomes. Understanding these core values provides insight into how HUTCHMED approaches its mission and interacts with stakeholders. More information about HUTCHMED's financial health can be found at: Breaking Down HUTCHMED (China) Limited (HCM) Financial Health: Key Insights for Investors

While specific details on HUTCHMED's formally stated core values are limited in the provided search results, the following values are evident in its actions and communications:

Innovation

Innovation is central to HUTCHMED's identity as a biopharmaceutical company. This involves a commitment to:

• Developing novel therapies for cancer and immunological diseases.
• Investing significantly in research and development (R&D). In 2024, HUTCHMED reported R&D expenses of $381.9 million.
• Advancing a pipeline of drug candidates, including both novel, targeted therapies and immunotherapies. As of 2024, the company's pipeline included several compounds in various stages of clinical development.

Integrity

Integrity is crucial in all aspects of HUTCHMED's operations, ensuring ethical conduct and transparency:

• Adhering to high ethical standards in clinical trials, data reporting, and regulatory compliance.
• Maintaining transparency with investors, partners, and the public regarding its financial performance and clinical development programs.
• Ensuring patient safety and well-being in all clinical studies and treatment protocols.

Patient-Centricity

A focus on improving patient outcomes is at the heart of HUTCHMED's mission:

• Developing therapies that address unmet medical needs in cancer and immunological diseases.
• Conducting clinical trials to evaluate the efficacy and safety of its drug candidates, with the goal of providing meaningful benefits to patients.
• Collaborating with healthcare professionals and patient advocacy groups to support patients and improve access to innovative treatments.

Collaboration

HUTCHMED emphasizes the importance of collaboration to achieve its goals:

• Partnering with academic institutions, research organizations, and other pharmaceutical companies to advance its R&D programs.
• Working closely with regulatory agencies to ensure the timely approval and availability of its therapies.
• Engaging with the medical community to educate healthcare professionals about its products and support their appropriate use.

Commitment to Quality

HUTCHMED is dedicated to maintaining high standards of quality in all its activities:

• Ensuring the quality and reliability of its manufacturing processes to produce safe and effective medicines.
• Implementing robust quality control measures throughout its supply chain.
• Continuously improving its processes and systems to meet the evolving needs of patients and healthcare providers.